New Drug Update - Including New Indications and Dosage Forms
After completing this course, the participant should be able to:
- Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications,
- Describe their adverse effects and drug interactions that may affect patient compliance,
- Compare efficacy, dosage and cost to existing agents.
- Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.
Course Content:
- FDA Safety Alerts
- Liraglutide – Victoza by Novo-Nordisk
- ADA/EASD and AACE/ACE Type 2 DM Guidelines
- Bromocriptine mesylate – Cycloset by VeroScience/Sanctura
- Pegloticase – Krystexxa by Savient
- Dabigatran – Pradaxa by Boehringer Ingelheim
- Dronedarone – Multaq by Sanofi Aventis
- ACCF/AHA/HRS Atrial Fibrillation Guideline Focused Update
- Pitavastatin - Livalo by Kowa and Lilly
- Drospirenone/ethinyl estradiol/levomefolate calcium tablets – Beyaz by Bayer
- Denosumab – Prolia by Amgen
- Risedronate delayed release
- Mometasone Furoate/Formoterol Fumarate for inhalation – Dulera by Merck/Schering
- Tranexamic Acid – Lysteda by Xanodyne
- Ulipristal acetate – ella by Watson
- Clonidine extended release – Kapvay by Shionogi
- Vilazodone HCl - Viibryd by Trovis
- Spinosad 0.9% Topical Suspension - Natroba by ParaPRO/Pernix
- Lurasidone HCl - Latuda by Sunovion
- Roflumilast – Daliresp by Forest
- Fingolimod - Gilenya by Novartis
- Buprenorphine Transdermal System - Butrans by Purdue Pharma
- Azilsartan – Edarbi by Takeda
- Boceprevir – Victrelis by Merck and Roche
- Telaprevir – Telaprevir by Vertex and Johnson & Johnson
